Welcome to CDC Stacks | Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children - 42161 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children
Filetype[PDF - 79.10 KB]


Details:
  • Pubmed ID:
    26935786
  • Pubmed Central ID:
    PMC5040162
  • Description:
    Objective

    Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care.

    Study design

    Children were eligible for enrollment if they presented to 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January–June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system (IIS). Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative.

    Results

    Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n=87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8–23months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively.

    Conclusions

    Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first two years of life.

  • Document Type:
  • Collection(s):
  • Funding:
    R25 MD007589/MD/NIMHD NIH HHS/United States
    U50 CK000196/CK/NCEZID CDC HHS/United States
    U54 MD007588/MD/NIMHD NIH HHS/United States
No Related Documents.
You May Also Like: